Shares of Coherus Biosciences Inc (NASDAQ:CHRS) were up 5.6% during trading on Friday . The stock traded as high as $18.58 and last traded at $18.55. Approximately 1,261,945 shares were traded during mid-day trading, an increase of 54% from the average daily volume of 819,809 shares. The stock had previously closed at $17.56.
Several analysts recently commented on CHRS shares. Robert W. Baird set a $28.00 price target on shares of Coherus Biosciences and gave the company a “buy” rating in a research report on Wednesday, April 10th. Zacks Investment Research upgraded shares of Coherus Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Wednesday. ValuEngine downgraded shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, May 4th. BidaskClub upgraded shares of Coherus Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, January 31st. Finally, Maxim Group set a $25.00 price target on shares of Coherus Biosciences and gave the company a “buy” rating in a research report on Friday, May 10th. Eight equities research analysts have rated the stock with a buy rating, Coherus Biosciences presently has a consensus rating of “Buy” and an average price target of $28.33.
The company has a current ratio of 3.84, a quick ratio of 2.49 and a debt-to-equity ratio of 8.29. The company has a market cap of $1.19 billion, a PE ratio of -5.76 and a beta of 3.64.
Coherus Biosciences (NASDAQ:CHRS) last announced its quarterly earnings data on Thursday, February 28th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.10). On average, research analysts anticipate that Coherus Biosciences Inc will post -0.8 EPS for the current year.
In other news, CFO Jean-Frederic Viret sold 3,000 shares of the company’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $14.92, for a total transaction of $44,760.00. Following the transaction, the chief financial officer now directly owns 13,185 shares of the company’s stock, valued at approximately $196,720.20. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 18.20% of the company’s stock.
Several large investors have recently bought and sold shares of CHRS. Deutsche Bank AG grew its stake in shares of Coherus Biosciences by 30.4% during the 4th quarter. Deutsche Bank AG now owns 2,382,438 shares of the biotechnology company’s stock worth $21,559,000 after purchasing an additional 555,972 shares during the period. Vanguard Group Inc grew its stake in Coherus Biosciences by 17.9% in the 3rd quarter. Vanguard Group Inc now owns 2,682,801 shares of the biotechnology company’s stock valued at $44,266,000 after acquiring an additional 406,520 shares during the last quarter. Vanguard Group Inc. grew its stake in Coherus Biosciences by 17.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,682,801 shares of the biotechnology company’s stock valued at $44,266,000 after acquiring an additional 406,520 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in Coherus Biosciences in the 1st quarter valued at about $3,501,000. Finally, Sivik Global Healthcare LLC acquired a new stake in Coherus Biosciences in the 1st quarter valued at about $3,069,000. 96.20% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Macon Daily and is the property of of Macon Daily. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://macondaily.com/2019/05/17/coherus-biosciences-chrs-trading-up-5-6.html.
About Coherus Biosciences (NASDAQ:CHRS)
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.
See Also: What are gap-up stocks?
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.